Millennium Management LLC bought a new position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 17,637 shares of the company's stock, valued at approximately $633,000. Millennium Management LLC owned 0.09% of USANA Health Sciences as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new stake in USANA Health Sciences in the 4th quarter valued at $83,000. Quantbot Technologies LP purchased a new stake in USANA Health Sciences in the 4th quarter worth about $132,000. Meeder Asset Management Inc. purchased a new stake in USANA Health Sciences in the 4th quarter worth about $143,000. Amundi increased its holdings in USANA Health Sciences by 85.3% in the 4th quarter. Amundi now owns 4,872 shares of the company's stock worth $170,000 after acquiring an additional 2,243 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA purchased a new stake in USANA Health Sciences in the 4th quarter worth about $206,000. 54.25% of the stock is owned by institutional investors and hedge funds.
USANA Health Sciences Price Performance
Shares of USANA Health Sciences stock opened at $29.34 on Friday. The business's 50 day simple moving average is $27.59 and its two-hundred day simple moving average is $31.41. The stock has a market capitalization of $546.31 million, a P/E ratio of 10.37, a price-to-earnings-growth ratio of 0.93 and a beta of 0.63. USANA Health Sciences, Inc. has a one year low of $23.10 and a one year high of $48.85.
USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.70 by $0.03. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The firm had revenue of $249.54 million for the quarter, compared to analysts' expectations of $243.08 million. During the same period in the previous year, the firm earned $0.86 earnings per share. Sell-side analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, CFO G Doug Iiekking sold 4,548 shares of the stock in a transaction on Friday, May 9th. The stock was sold at an average price of $29.61, for a total transaction of $134,666.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider David Mulham Mulham sold 3,234 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the sale, the insider now directly owns 12,775 shares in the company, valued at $421,319.50. This trade represents a 20.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,979 shares of company stock valued at $655,146 over the last ninety days. Company insiders own 0.63% of the company's stock.
Wall Street Analysts Forecast Growth
USNA has been the subject of several analyst reports. DA Davidson cut their target price on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, February 27th. Wall Street Zen upgraded USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Finally, Sidoti downgraded USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th.
Check Out Our Latest Analysis on USANA Health Sciences
USANA Health Sciences Company Profile
(
Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
